A share price of Vera Therapeutics Inc [VERA] is currently trading at $29.41, up 5.91%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VERA shares have lost -0.68% over the last week, with a monthly amount drifted -18.26%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vera Therapeutics Inc [NASDAQ: VERA] stock has seen the most recent analyst activity on February 04, 2025, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $49. Previously, Goldman started tracking the stock with Buy rating on January 28, 2025, and set its price target to $58. On November 21, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $70 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating. Oppenheimer initiated its recommendation with a Outperform and recommended $26 as its price target on January 25, 2024. In a note dated December 18, 2023, Raymond James initiated an Outperform rating and provided a target price of $29 on this stock.
Vera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $25.99 and $51.61. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Vera Therapeutics Inc [NASDAQ: VERA] shares were valued at $29.41 at the most recent close of the market. An investor can expect a potential drop of -11.59% based on the average VERA price forecast.
Analyzing the VERA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.5 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.39 points at the first support level, and at 27.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.27, and for the 2nd resistance point, it is at 31.13.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vera Therapeutics Inc [NASDAQ:VERA] is 25.67. As well, the Quick Ratio is 13.60, while the Cash Ratio is 1.03.
Transactions by insiders
Recent insider trading involved Fordyce Marshall, PRESIDENT AND CEO, that happened on Feb 21 ’25 when 10613.0 shares were sold. PRESIDENT AND CEO, Fordyce Marshall completed a deal on Feb 26 ’25 to sell 9075.0 shares. Meanwhile, Director MARSHALL FORDYCE bought 9075.0 shares on Feb 26 ’25.
